Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study
- PMID: 21357908
- DOI: 10.7326/0003-4819-154-5-201103010-00005
Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study
Abstract
Background: Glomerular filtration rate and albuminuria are risk factors for cardiovascular disease and markers of renal function.
Objective: To examine the contribution of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio beyond that of traditional cardiovascular risk factors to classification of patient risk for cardiovascular and renal outcomes.
Design: Prospective cohort study that pooled all patients of ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease).
Patients: 27,620 patients older than 55 years with documented cardiovascular disease, who were followed for a mean of 4.6 years.
Measurements: Baseline eGFR, urinary albumin-creatinine ratio, and cardiovascular risk factors. Outcomes were all-cause mortality; a composite of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure; long-term dialysis; and a composite of long-term dialysis and doubling of serum creatinine level.
Results: Lower eGFRs and higher urinary albumin-creatinine ratios were associated with the primary cardiovascular composite outcome (for example, an adjusted hazard ratio of 2.53 [95% CI, 1.61 to 3.99] for an eGFR <30 mL/min per 1.73 m(2) and a very high urinary albumin-creatinine ratio). However, adding information about eGFR and urinary albumin-creatinine ratio to the risk reclassification analyses led to no meaningful decrease in the proportion of patients assigned to the intermediate-risk category (31% without vs. 32% with renal information). In contrast, eGFR and urinary albumin-creatinine ratio were strongly associated with risk for long-term dialysis and greatly improved both model calibration and risk stratification capacity when added to traditional cardiovascular risk factors (65% assigned to intermediate-risk categories without renal information vs. 18% with renal information).
Limitation: Creatinine levels were not standardized.
Conclusion: In patients with high vascular risk, eGFR and urinary albumin-creatinine ratio add little to traditional cardiovascular risk factors for stratifying cardiovascular risk but greatly improve risk stratification for renal outcomes.
Primary funding source: Boehringer Ingelheim, Population Health Research Institute, and the European Commission.
Similar articles
-
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28. Circulation. 2011. PMID: 21357827 Clinical Trial.
-
Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.Am J Kidney Dis. 2021 Mar;77(3):386-396.e1. doi: 10.1053/j.ajkd.2020.09.015. Epub 2020 Nov 14. Am J Kidney Dis. 2021. PMID: 33197533
-
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21. Am J Kidney Dis. 2021. PMID: 32971190 Clinical Trial.
-
Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.BMJ. 2013 Jan 29;346:f324. doi: 10.1136/bmj.f324. BMJ. 2013. PMID: 23360717 Free PMC article. Review.
-
The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.Cardiorenal Med. 2020;10(1):1-10. doi: 10.1159/000503919. Epub 2019 Nov 19. Cardiorenal Med. 2020. PMID: 31743918
Cited by
-
Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US population.Am J Kidney Dis. 2014 May;63(5):753-60. doi: 10.1053/j.ajkd.2013.11.014. Epub 2013 Dec 25. Am J Kidney Dis. 2014. PMID: 24369751 Free PMC article.
-
Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study.Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1770-7. doi: 10.1161/ATVBAHA.114.303465. Epub 2014 May 29. Arterioscler Thromb Vasc Biol. 2014. PMID: 24876355 Free PMC article.
-
Association of pre-operative estimated GFR on post-operative pulmonary complications in laparoscopic surgeries.Sci Rep. 2017 Jul 26;7(1):6504. doi: 10.1038/s41598-017-06842-4. Sci Rep. 2017. PMID: 28747700 Free PMC article.
-
Life's Essential 8 cardiovascular health, cardiovascular-kidney-metabolic syndrome stages, and incident cardiovascular events: a nationwide 10-year prospective cohort study in China.Cardiovasc Diabetol. 2025 May 9;24(1):197. doi: 10.1186/s12933-025-02735-3. Cardiovasc Diabetol. 2025. PMID: 40346555 Free PMC article.
-
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).Am J Kidney Dis. 2015 Sep;66(3):429-40. doi: 10.1053/j.ajkd.2015.02.324. Epub 2015 Apr 29. Am J Kidney Dis. 2015. PMID: 25935581 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous